The increasing prevalence of oral oncolytics use, further accelerated by COVID-19, heightens the need for strong patient-pharmacist treatment coordination.
Amanda Manoogian, PharmD, BCOP
Advertisement
Articles by Amanda Manoogian, PharmD, BCOP
Advertisement
Latest Updated Articles
COVID-19 and the Impact on Oral Oncolytics: A Specialty Pharmacy PerspectivePublished: August 26th 2020 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
MFN, DTC, and the Policy Pressure Cooker: Reshaping the US Drug Market
2
Oral Semaglutide Shows Promise for Weight Loss and Cardiometabolic Health
3
FDA Approves Lumateperone With Antidepressant Use for Major Depressive Disorder
4
A Review of Antibody-Drug Conjugates for the Treatment of Urothelial Carcinoma: The Rise of Enfortumab Vedotin
5
